Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated d... by Taylor, P, Takeuchi, T, Burmester, GR, Durez, P, Smolen, JS, Deberdt, W, Issa, M, Terres, JR, Bello, N, Winthrop, K

Baricitinib, tofacitinib, upadacitinib, filgotinib, and cytokine signaling in human leukocyte subpopulations: an updated ex-vivo comparison by McInnes, IB, Rocha, G, Higgs, R, Dairaghi, D, Wehrman, T, Wang, E, Zhang, X, Terres, JR, Rooney, T, Taylor, PC

Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy by Taylor, P, Alten, R, Álvaro-Gracia, JM, Kaneko, Y, Walls, C, Quebe, A, Jia, B, Bello, N, Terres, JR, Fleischmann, RM